BCYC Relative Valuation
BCYC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BCYC is overvalued; if below, it's undervalued.
Historical Valuation
Bicycle Therapeutics PLC (BCYC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.81. The fair price of Bicycle Therapeutics PLC (BCYC) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：7.14
Fair
-2.07
PE
1Y
3Y
5Y
Trailing
Forward
0.71
EV/EBITDA
Bicycle Therapeutics PLC. (BCYC) has a current EV/EBITDA of 0.71. The 5-year average EV/EBITDA is -4.27. The thresholds are as follows: Strongly Undervalued below -13.50, Undervalued between -13.50 and -8.89, Fairly Valued between 0.35 and -8.89, Overvalued between 0.35 and 4.97, and Strongly Overvalued above 4.97. The current Forward EV/EBITDA of 0.71 falls within the Overvalued range.
0.55
EV/EBIT
Bicycle Therapeutics PLC. (BCYC) has a current EV/EBIT of 0.55. The 5-year average EV/EBIT is -4.09. The thresholds are as follows: Strongly Undervalued below -13.15, Undervalued between -13.15 and -8.62, Fairly Valued between 0.45 and -8.62, Overvalued between 0.45 and 4.98, and Strongly Overvalued above 4.98. The current Forward EV/EBIT of 0.55 falls within the Overvalued range.
17.88
PS
Bicycle Therapeutics PLC. (BCYC) has a current PS of 17.88. The 5-year average PS is 42.28. The thresholds are as follows: Strongly Undervalued below -8.25, Undervalued between -8.25 and 17.02, Fairly Valued between 67.55 and 17.02, Overvalued between 67.55 and 92.81, and Strongly Overvalued above 92.81. The current Forward PS of 17.88 falls within the Historic Trend Line -Fairly Valued range.
-2.00
P/OCF
Bicycle Therapeutics PLC. (BCYC) has a current P/OCF of -2.00. The 5-year average P/OCF is -8.35. The thresholds are as follows: Strongly Undervalued below -18.59, Undervalued between -18.59 and -13.47, Fairly Valued between -3.23 and -13.47, Overvalued between -3.23 and 1.89, and Strongly Overvalued above 1.89. The current Forward P/OCF of -2.00 falls within the Overvalued range.
-1.85
P/FCF
Bicycle Therapeutics PLC. (BCYC) has a current P/FCF of -1.85. The 5-year average P/FCF is -7.37. The thresholds are as follows: Strongly Undervalued below -17.22, Undervalued between -17.22 and -12.29, Fairly Valued between -2.45 and -12.29, Overvalued between -2.45 and 2.48, and Strongly Overvalued above 2.48. The current Forward P/FCF of -1.85 falls within the Overvalued range.
Bicycle Therapeutics PLC (BCYC) has a current Price-to-Book (P/B) ratio of 0.80. Compared to its 3-year average P/B ratio of 1.93 , the current P/B ratio is approximately -58.55% higher. Relative to its 5-year average P/B ratio of 2.96, the current P/B ratio is about -72.95% higher. Bicycle Therapeutics PLC (BCYC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -17.84%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -12.82% , the current FCF yield is about -100.00% lower.
0.80
P/B
Median3y
1.93
Median5y
2.96
-48.83
FCF Yield
Median3y
-17.84
Median5y
-12.82
Competitors Valuation Multiple
The average P/S ratio for BCYC's competitors is 0.00, providing a benchmark for relative valuation. Bicycle Therapeutics PLC Corp (BCYC) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 338.49%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BCYC decreased by 49.00% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 2.68M to 11.73M.
The secondary factor is the Margin Expansion, contributed -73.47%to the performance.
Overall, the performance of BCYC in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Bicycle Therapeutics PLC (BCYC) currently overvalued or undervalued?
What is Bicycle Therapeutics PLC (BCYC) fair value?
How does BCYC's valuation metrics compare to the industry average?
What is the current P/B ratio for Bicycle Therapeutics PLC (BCYC) as of Dec 05 2025?
What is the current FCF Yield for Bicycle Therapeutics PLC (BCYC) as of Dec 05 2025?
What is the current Forward P/E ratio for Bicycle Therapeutics PLC (BCYC) as of Dec 05 2025?